Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674429 | 0.97 | ACE (0.50) | ACELMNAFKBP1AAGTR2 | |
| SCHEMBL26616455 | 0.91 | ACE (0.64) | ACELMNASMN1; SMN2 | |
| SCHEMBL26616380 | 0.91 | ACE (0.64) | ACELMNASMN1; SMN2 | |
| SCHEMBL31376307 | 0.91 | ACE (0.64) | ACELMNASMN1; SMN2 | |
| SCHEMBL26616457 | 0.91 | ACE (0.64) | ACELMNASMN1; SMN2 | |
| SCHEMBL26616386 | 0.91 | ACE (0.64) | ACELMNASMN1; SMN2 | |
| SCHEMBL9814462 | 0.90 | ACE (0.49) | ACEFKBP1A | |
| SCHEMBL31376312 | 0.89 | ACE (0.57) | ACELMNASMN1; SMN2 | |
| SCHEMBL30674426 | 0.89 | ACE (0.57) | ACELMNASMN1; SMN2 | |
| SCHEMBL26616543 | 0.89 | ACE (0.57) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| EP-4514781-A1 | PREP BINDING LIGANDS | Polku Therapeutics OY (FI) | 2025-03-05 | — | — | EP | disclosed |
| CN-119451944-A | PREP binding ligands | 珀尔库治疗有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| EP-0201741-B1 | DIPEPTIDE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION AND USE | SUNTORY LIMITED (JP) | 1991-07-31 | — | — | EP | disclosed |
| US-4873342-A | ANTI-AMNESIC AGENT | SUNTORY LIMITED (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0201741-A2 | Dipeptide derivatives, processes for preparing them, pharmaceutical composition and use | SUNTORY LIMITED (JP) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | ACE 1037/4885LMNA 1543/4885FKBP1A 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.